Prophylactic recombinant factor VIIa in haemophilia patients with inhibitors

Haemophilia

Volumn 11, Issue 3, 2005, Pages 203-207

  Young, Guy ^a   McDaniel, M ^a   Nugent, D J ^a  

^a CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

Author keywords

Haemophilia; Inhibitors; Prophylaxis; Recombinant factor VIIa

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; NEUTRALIZING ANTIBODY; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

ADOLESCENT; ARTICLE; BLEEDING; CASE REPORT; CHEMOPROPHYLAXIS; DRUG COST; DRUG RESPONSE; DRUG USE; HEMOPHILIA; HOSPITALIZATION; HUMAN; MALE; PATIENT SELECTION; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY OF LIFE;

ADOLESCENT; AUTOANTIBODIES; CHILD, PRESCHOOL; FACTOR VII; FACTOR VIII; HEMARTHROSIS; HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGE; HUMANS; MALE; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES;

EID: 19444375983     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2005.01096.x     Document Type: Article

References (9)

1. Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients - a long-term follow-up. J Intern Med 1997; 241: 395-400.
2. Darby SC, Keeling DM, Spooner RJ et al. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99. J Thromb Haemost 2004; 2: 1047-54.
3. DiMichele D. Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia 2002; 8: 280-7.
4. Hilgartner MW, Makipernaa A, Dimichele DM. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease. Haemophilia 2003; 9: 261-8.
5. Leissinger CA. Use of prothrombin complex concentrates and activated prothrombin complex concentrates as prophylactic therapy in hemophilia patients with inhibitors. Haemophilia 1999; 5(Suppl. 3): 25-32.
6. Cooper HA, Jones CP, Campion E, Roberts HR, Hedner U. Rationale for the use of high dose rFVIIa in a high-titre inhibitor patient with hemophilia B during major orthopedic procedures. Haemophilia 2001; 7: 517-22.
7. Saxon BR, Shanks D, Jory CB, Williams V. Effective prophylaxis with daily recombinant factor VIIa (rFVIIa-Novoseven) in a child with high titre inhibitors and a target joint. Thromb Haemost 2001; 86: 1126-7.
8. Schneiderman J, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa, in patients with severe haemophilia and inhibitors. Haemophilia 2004; 10: 347-51.
9. Ehrlich HJ, Henzel MJ, Gomperts ED. Safety of FVIII inhibitor bypass activity (FEIBA): 10 year compilation of thrombotic adverse events. Haemophilia 2002; 8: 83-90.